Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eloxx PharmaceuticalsELOX -3.29%17 EV-to-EBITDA is -11.19 as of Aug. 06, 2026. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 409 Biotechnology companies, Eloxx Pharmaceuticals ranks worse than 244498.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eloxx Pharmaceuticals's enterprise value is $55.35 Mil.
Eloxx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-EBITDA for today is -11.19.
The historical rank and industry rank for Eloxx Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ELOX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.15 Med: -0.28 Max: 0.09
Current: -11.19
During the past 13 years, the highest EV-to-EBITDA of Eloxx Pharmaceuticals was 0.09. The lowest was -12.15. And the median was -0.28.
ELOX's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs ELOX: -11.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eloxx Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Eloxx Pharmaceuticals's share price for today is $17.21.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Eloxx Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Eloxx Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eloxx Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eloxx Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eloxx Pharmaceuticals's EV-to-EBITDA falls into.
Eloxx Pharmaceuticals's current Enterprise Value is $55.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eloxx Pharmaceuticals (ELOX) has a EV-to-EBITDA of -11.19 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eloxx Pharmaceuticals. According to the industry distribution chart, Eloxx Pharmaceuticals ranks #999999 out of 409 companies in the Biotechnology industry.
Is Eloxx Pharmaceuticals' EV-to-EBITDA too high?
Eloxx Pharmaceuticals' current EV-to-EBITDA is -11.19. Based on the distribution chart, Eloxx Pharmaceuticals ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' EV-to-EBITDA compare to APLM and FLNA?
According to the Biotechnology industry distribution chart, Eloxx Pharmaceuticals ranks #999999 out of 409 companies for EV-to-EBITDA. This places Eloxx Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eloxx Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eloxx Pharmaceuticals's current EV-to-EBITDA is -11.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current EV-to-EBITDA of -11.19. The current EV-to-EBITDA is -11.19. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current EV-to-EBITDA is -11.19 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score
Get the complete analysis for ELOX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELOX has been successfully added to your 
